B2M

B2M
Name	Beta-2-microglobulin
Alt	Beta-2-microglobulin structure
Caption	Crystal structure of beta-2-microglobulin
Uniprot	P61769
Gene	B2M
Organism	Human
Length	119 aa
Mass	~11.8 kDa

B2M

Beta-2-microglobulin is a small, non-glycosylated polypeptide component of class I major histocompatibility complex (MHC I) molecules found on the surface of nearly all nucleated human cells. It associates non-covalently with the heavy chain of MHC I and participates in peptide presentation to cytotoxic lymphocytes, with relevance across immunology, nephrology, hematology, oncology, and transplantation medicine.

Definition and Nomenclature

Beta-2-microglobulin is defined as the light chain subunit of MHC I molecules encoded by the B2M gene on chromosome 15. Nomenclature and synonyms include B2M protein, beta-2 microglobulin, and light chain of HLA class I; standardized entries appear in UniProt, HGNC, OMIM, and the Human Protein Atlas. Historical descriptions tie the protein to early antibody-mediated studies at institutions such as the Pasteur Institute, the NIH, and the Wellcome Trust, and to investigators like Jean Dausset and Baruj Benacerraf who contributed to HLA research.

Biology and Function

B2M non-covalently binds to HLA-A, HLA-B, and HLA-C heavy chains and stabilizes the peptide-binding groove, enabling antigenic peptide presentation to CD8+ T lymphocytes, natural killer cells, and invariant natural killer T cells. The molecule is involved in MHC class I assembly in the endoplasmic reticulum with chaperones such as calnexin, calreticulin, and tapasin, and it influences interactions with the transporter associated with antigen processing (TAP), proteasome-derived peptides, and the immunoproteasome components LMP2 and LMP7. Extracellularly, liberated B2M circulates and is cleared by glomerular filtration in the kidney; dysregulation affects complement activation, cytokine networks including interferons and interleukins, and cellular processes implicated in amyloidogenesis.

Clinical Significance and Biomarker Use

Serum and urine concentrations of beta-2-microglobulin serve as biomarkers in diverse clinical contexts: they are used in staging and prognosis of multiple myeloma, chronic lymphocytic leukemia, and lymphoma; they indicate renal tubular dysfunction in Fanconi syndrome, nephropathies, and transplant rejection; and they are monitored in HIV infection, hepatitis, and autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Elevated levels predict outcomes in cardiovascular disease cohorts, dialysis-associated complications, and dialysis-related amyloidosis among long-term hemodialysis patients. Organizations and trials from the American Society of Hematology, European LeukemiaNet, and WHO have incorporated B2M measurements into diagnostic algorithms and staging criteria for hematologic malignancies.

Measurement Methods and Laboratory Considerations

Laboratory quantification employs immunoassays including enzyme-linked immunosorbent assay (ELISA), nephelometry, turbidimetry, and multiplex immunoassays validated by clinical laboratories affiliated with centers like Mayo Clinic, Johns Hopkins, and Mount Sinai. Preanalytical variables include sample type (serum vs. urine), collection timing, hemolysis, and storage conditions; renal function, dialysis modality (hemodialysis, peritoneal dialysis), and medications influence interpretation. Reference ranges are provided by CLSI guidelines and national pathology services; assay standardization aligns with International Federation of Clinical Chemistry recommendations. Laboratories must account for analytical interferences from monoclonal paraproteins in myeloma, heterophile antibodies, and high-dose biotherapeutics used in oncology and rheumatology trials.

Genetic and Molecular Variants

The B2M gene on chromosome 15 encodes a conserved beta-sandwich fold; pathogenic variants include loss-of-function mutations associated with hereditary amyloidosis and rare immunodeficiency phenotypes. Somatic B2M mutations occur in tumor immune escape, notably in mismatch repair–deficient colorectal cancers, melanoma, and Hodgkin lymphoma, where frameshift and nonsense mutations abrogate MHC I expression and confer resistance to checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies. Polymorphisms and splice variants have been cataloged in dbSNP, gnomAD, and COSMIC, and epigenetic regulation of B2M expression has been described in studies by institutions like Memorial Sloan Kettering, Dana-Farber, and the Broad Institute.

Therapeutic and Research Implications

Therapeutic strategies target B2M-related pathways in oncology, transplantation, and dialysis medicine. In cancer immunotherapy, loss of B2M is a biomarker of acquired resistance to immune checkpoint blockade assessed in trials at MD Anderson and the National Cancer Institute; strategies to overcome resistance include adoptive T-cell therapies, neoantigen vaccines, and bispecific antibodies developed by biotech firms and academic consortia. In nephrology, efforts to reduce beta-2-microglobulin amyloid deposition involve high-flux dialysis membranes, renal transplantation, and investigational amyloid inhibitors evaluated in multicenter trials across Europe and North America. Research applications include structural biology studies using cryo-EM and X-ray crystallography at EMBL and RIKEN, proteomic profiling in clinical cohorts led by the Karolinska Institute and Stanford, and genome-editing experiments using CRISPR at universities such as Harvard and University of California to model B2M loss in tumor immune escape.

Category:Proteins